MedTrace Logo

Treatment for Patients With Gynecological Malignancies Who Suffer From Anemia Due to Chemotherapy

NCT00121030 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2007-12-24

No results posted yet for this study

Summary

The purpose of this study is to validate a Patient Satisfaction Questionnaire for Anemia Treatment (PSQ-AT) in gynecological cancer patients treated with darbepoetin alfa or recombinant human erythropoietin (rHuEPO) for anemia due to chemotherapy.

Conditions

  • Gynecological Malignancies
  • Genital Neoplasms, Female
  • Anemia

Interventions

DRUG

darbepoetin alfa

DRUG

recombinant human erythropoietin (rHuEPO)

Sponsors & Collaborators

Principal Investigators

  • MD · Amgen

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2002-10-31
Completion
2003-12-31

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00121030 on ClinicalTrials.gov